Developing a new class of orally available RNA-targeting medicines
Wayfinder Bio stops key disease proteins before they’re even made using a new class of orally available RNA-targeting medicines.
Most diseases are driven by disregulated proteins. Traditional therapies try to block these proteins directly, but many key targets remain untreatable despite decades of research. We take a different approach—stopping harmful proteins before they’re even made. We develop small molecules that bind to the mRNAs encoding these proteins, preventing their production in the first place.
We are building a pipeline of small molecule assets for targets inaccessible by traditional drug development approaches.
Our platform discovers selective molecules that target specific RNA pockets
Centered around Wayfinder Bio’s unique RNA-based sensors and data generation engine, our proprietary technology combines experimental and AI/ML screening to discover potent, selective and biologically active RNA-targeting small molecules. The Wayfinder platform powers a scalable approach for uniquely quantitative insights not only on the binding of small molecules to RNA, but also on their selectivity and function.
Our Pipeline
| Target | Indication | Target ID | Discovery | Hit-To-Lead | Program |
|---|---|---|---|---|---|
| c-MYC | Oncology |  |
|||
| Multiple targets | Undisclosed | |
|||
| Undisclosed | Neurodegeneration |
collaboration
|
Our technology is broadly applicable to RNA targets across disease areas and indications.
Partnering areas of interest include oncology, neurodegeneration, immunology, rare disease.